手术创伤诱发的获得性凝血因子Ⅴ抑制物合并致命性出血一例并文献复习
报告2022年上海市东方医院重症医学科收治的1例56岁男性术后凝血功能紊乱患者,凝血因子Ⅴ活性8.4%、抑制物滴度8 BU/ml,混合血浆纠正试验即刻和延迟2小时均无法纠正,经糖皮质激素、环磷酰胺及血浆置换后凝血异常纠正;文献检索到国内报道16例、全球累计近200例。
要点
- 获得性凝血因子Ⅴ抑制物患者临床表现多样,混合血浆纠正试验即刻和延迟2小时均无法纠正提示存在抑制物。
- 该例凝血因子Ⅴ活性8.4%且持续下降,抑制物滴度8 BU/ml,考虑手术创伤诱发。
- 现有治疗包括支持治疗、糖皮质激素、免疫抑制剂、血浆置换及联合治疗,预后取决于诱发因素及诊治时效性。
核心结论
- 获得性凝血因子Ⅴ抑制物患者临床表现多样,现有治疗手段包括支持治疗、糖皮质激素、免疫抑制剂、血浆置换及联合治疗,患者预后取决于诱发因素及诊治的时效性。
研究设计与样本
- 对2022年上海市东方医院重症医学科收治的1例获得性凝血因子Ⅴ抑制物患者进行分析,并以 PubMed 及中文数据库(万方、维普、中国知网)进行文献检索和复习。
主要发现
- 患者为56岁男性,因术后凝血功能紊乱伴腹腔出血转入重症医学科,血常规正常,凝血酶原时间76.7 s、活化部分凝血活酶时间83.1 s、国际标准化比值7.14。
- 凝血因子Ⅴ活性8.4%且呈持续下降,混合血浆纠正试验即刻和延迟2 h均无法纠正,凝血因子Ⅴ抑制物滴度为8 BU/ml。
- 考虑因手术创伤诱发获得性凝血因子Ⅴ抑制物生成并导致致命性出血,予激素、环磷酰胺并血浆置换治疗后凝血异常纠正。
- 文献检索共检索到国内报道16例,全球累计报道近200例。
关键数值与推荐
- 凝血酶原时间76.7 s、活化部分凝血活酶时间83.1 s、国际标准化比值7.14。
- 凝血因子Ⅴ活性8.4%且呈持续下降,凝血因子Ⅴ抑制物滴度8 BU/ml。
- 混合血浆纠正试验即刻和延迟2 h均无法纠正。
临床怎么用
- 现有治疗手段包括支持治疗、糖皮质激素、免疫抑制剂、血浆置换及联合治疗。
- 患者预后取决于诱发因素及诊治的时效性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the diagnosis, treatment, and prognosis of patients with acquired factor Ⅴ inhibitors. Methods: We analyzed a case of acquired factor Ⅴ inhibitor treated in the department of critical care medicine at Shanghai East Hospital in 2022. A literature review was conducted using the search terms [ ("Factor V" OR "Factor V Inhibitors") AND ("Autoantibodies" OR "Immune System Diseases") ] AND [acquired (Title/Abstract) OR autoimmune (Title/Abstract) OR inhibitor (Title/Abstract) ] in the PubMed database. Chinese databases (Wanfang, VIP, and CNKI) were searched using (acquired factor V inhibitor OR acquired coagulation factor V inhibitor OR coagulation factor V antibody OR coagulation factor V autoantibody) AND (deficiency OR inhibition OR dysfunction) . Results: A 56-year-old male was admitted to the department of critical care medicine due to coagulopathy following surgery. Laboratory tests showed normal blood routine but revealed prolonged PT of 76.7 s, APTT of 83.1 s, and an INR of 7.14. Coagulation factor assays indicated factor V activity at 8.4%, which continued to decline. Immediate and 2-hour delayed mixing studies failed to correct the coagulation abnormalities. The factor V inhibitor titer was measured at 8 BU/ml. It was considered that surgical trauma induced the production of an acquired factor V inhibitor, leading to fatal bleeding. After treatment with corticosteroids, cyclophosphamide, and plasma exchange, the coagulation abnormalities were corrected. The literature search identified 16 cases reported in China and approximately 200 cases reported globally. Conclusion: Patients with acquired factor V inhibitors exhibit diverse clinical manifestations. Current treatment options include combined therapies such as supportive care, corticosteroids, immunosuppressants, and plasma exchange. The prognosis of patients depends on the inducing factors and the timeliness of diagnosis and treatment. 目的: 探讨获得性凝血因子Ⅴ抑制物患者的诊治方法及预后。 方法: 对2022年上海市东方医院重症医学科收治的1例获得性凝血因子Ⅴ抑制物患者进行分析。并以[("Factor Ⅴ" OR "Factor Ⅴ Inhibitors")AND("Autoantibodies" OR "Immune System Diseases")] AND [acquired(Title/Abstract)OR autoimmune(Title/Abstract)OR inhibitor(Title/Abstract)]为检索式在PubMed数据库进行检索,以(获得性第五因子抑制物OR获得性凝血因子Ⅴ抑制物OR凝血因子Ⅴ抗体OR凝血因子Ⅴ自身抗体)AND(缺乏OR抑制OR功能障碍)为检索式在中文数据库(万方、维普、中国知网)中进行检索并文献复习。 结果: 患者为56岁男性,因术后凝血功能紊乱伴腹腔出血转入我科。辅助检查示血常规正常,凝血功能示凝血酶原时间(PT)76.7 s,活化部分凝血活酶时间(APTT)83.1 s,国际标准化比值(INR)7.14。凝血因子活性示Ⅴ因子8.4%且呈持续下降。混合血浆纠正试验示即刻和延迟2 h均无法纠正。凝血因子抗体滴度示Ⅴ因子抑制物8 BU/ml。考虑因手术创伤诱发获得性凝血因子Ⅴ抑制物生成,并导致致命性出血。予激素、环磷酰胺并血浆置换治疗后凝血异常纠正。文献检索共检索到国内报道16例,全球累计报道近200例。 结论: 获得性凝血因子Ⅴ抑制物患者临床表现多样,现有治疗手段包括支持治疗、糖皮质激素、免疫抑制剂、血浆置换及联合治疗,患者预后取决于诱发因素及诊治的时效性。.
引用
- Zhang YH, Pan X, Chu XX, et al. [Acquired factor Ⅴ inhibitor induced by surgical trauma complicated with fatal hemorrhage: a case report and literature review]. Zhonghua Xue Ye Xue Za Zhi. 2024. PMID: 40032336. doi:10.3760/cma.j.cn121090-20241128-00491
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。